Abstract-Chronic lymphocytic leukemia (CLL) is the most common peripheral blood and bone marrow cancer in the developed world. This manuscript proposes mathematical model equations representing the disease dynamics of B-cell CLL. We interconnect delay differential cell cycle models in each of the tumorinvolved disease centers using physiologically relevant cell migration. We further introduce five hypothetical case studies representing CLL heterogeneity commonly seen in clinical practice and demonstrate how the proposed CLL model framework may capture disease pathophysiology across patient types. We conclude by exploring the capacity of the proposed temporally-and spatially distributed model to capture the heterogeneity of CLL disease progression. By using global sensitivity analysis, the critical parameters influencing disease trajectory over space and time are: 1) the initial number of CLL cells in peripheral blood, the number of involved lymph nodes, the presence and degree of splenomegaly; 2) the migratory fraction of nonproliferating as well as proliferating CLL cells from bone marrow into blood and of proliferating CLL cells from blood into lymph nodes; and 3) the parameters inducing nonproliferative cells to proliferate. The proposed model offers a practical platform that may be explored in future personalized patient protocols once validated.
I. INTRODUCTION
C HRONIC lymphocytic leukemia (CLL) is the most common peripheral blood and bone marrow cancer in the developed world, usually afflicting older individuals [1] . It is a heterogeneous disease consisting of abnormal proliferation and This paper has supplementary downloadable material available at http://ieee xplore.ieee.org (File size: 2.04_MB).
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Digital Object Identifier 10.1109/TBME.2016.2533658 [8] - [10] , [19] , [20] CLL reduced apoptosis in mutated clones, most commonly of mature B-cells, resulting in accumulation in four compartments: the bone arrow, peripheral blood, lymph nodes, and spleen. Initial chromosomal mutations differ between patients and malignant transformations progress variably. Subclonal mutations may arise and overtake the dominant clone because of other stressors, such as chemotherapy used to treat the original disease [2] . The site of primary CLL pathogenesis is the lymph nodes and/or bone marrow with cells then circulating in peripheral blood and homing preferentially toward bone marrow, lymph nodes, or spleen depending on expression of chemokine receptors or intracellular proteins [3] - [5] ; this heterogeneity results in variable presentations of lymphocytosis, bone marrow failure, lymphadenopathy, and splenomegaly [6] , [7] with the clinical stages of disease defined using the Binet [8] or Rai [9] systems and WHO [10] criteria for diagnosis (see Table I ). The disease typically progresses slowly with most CLL cells arrested in the resting (G0) or growth (G1) phases of the cell cycle [11] . Since CLL has defined mutations predictive of prognosis and a chronic trajectory often spanning decades, we hypothesize that mathematical models may characterize CLL disease dynamics with the potential to act as a framework for personalized treatment strategies.
Diverging from previous mathematical models for B-cell CLL (hereafter, referred to as CLL), this manuscript presents the first personalized, physiologically relevant mathematical framework modeling CLL with features that 1) consider each of the most relevant disease centers including those of bone marrow, peripheral blood, lymph nodes, and spleen, 2) interconnect the affected tissues via descriptors for cell migration, 3) calculate migration rates between affected tissues, and 4) provide a framework to predict CLL progression over the disease course, in the absence of treatment. This study belongs to an ongoing effort developing building blocks for modeling and optimizing biomedical systems [12] such as that for acute myeloid leukemia [13] , [14] , Type 1 diabetes mellitus [15] , and for the delivery of anesthesia [16] , [17] . We previously performed a more limited global sensitivity analysis than that described in Online Supplement Appendix F [18] ; otherwise the manuscript is all new.
II. MATHEMATICAL MODEL
The model (see Fig. 1 ) consists of three cell cycle models and the interconnectivity between them; we assume that CLL cells are distributed in bone marrow (BM), peripheral blood (PB), and lymph nodes (LNs) and spleen (S) at the point of diagnosis and that S is aggregated with LN.
A. CLL
Our model (see Fig. 1 ) is a general framework that captures the following dynamics: as CLL cells proliferate in BM (as captured at diagnosis the prediagnosis disease-initiating mutation(s) may occur in either LN or S, and then, populate BM), the cells may either migrate to peripheral blood, and then, LN or stay in BM. It includes three cell cycles and migration rates for both proliferative (P ) and nonproliferative (N ) CLL cells from BM to PB (BM2PB), and then, to LN (PB2LN); this model applies to naïve stage and Binet stages A-C (SN, SA, SB, SC). Equations (1)-(12) represent the specific case where: 1) the Mackey [23] G0 model (Appendix A) is correct and b) we have data regarding lymphocyte counts and proliferation in affected tissues (see Tables I and II) . While we limit our analysis to a proliferating/nonproliferating model [23] , an equivalent development could be constructed for a detailed G1 → S → G2/M cell cycle model, e.g., [24] .
Before defining the three interconnected G0 models in (7)- (12), we define time delay (1), proliferation feedback function (2) and (3), and the relationship between Ki-67 expression, i.e., percent proliferation, and cell numbers for each disease center i ∈ {BM, PB, LN} and disease stage z ∈ {SN, SA, SB, SC}
Ki-
In (2) feedback function, β N i , 0 is the maximum recruitment in each tissue [25] . Fig. 2 illustrates (2) for n = 3 and demonstrates that control parameter θ i modulates recruitment from nonproliferative (N i ) and proliferative (P i ) phases. The θ i value is larger in CLL proliferation centers, i.e., BM, LN, and S, than in the accumulation compartment (PB) where the expression of proliferative marker Ki-67 is lowest [26] . The BM disease center has restricted volume (BM max ≈ 13.5 × 10 11 lymphocytes; Appendix B). Assuming that the normal lymphocyte count in BM remains constant, carrying capacity, cc, represents restricted volume [27] , a BM is the percentage of normal lymphocytes in BM (see Appendix B), and C NC, BM is the number of lymphocytes in normal BM (see Table II )
BM equations (7) and (8) hold ∀ z ∈ {SN, SA, SB, SC}
PB equations (9) and (10) hold ∀ z ∈ {SN, SA, SB, SC}
LN equations (11) and (12) hold ∀ z ∈ {SN, SA, SB, SC}
B. Algorithm for Determining Cell Cycle Parameters
The model is an index-1 system with 6 differential and 23 algebraic equations, 76 parameters (22 assumed, 38 calculated, 10 measured, 6 initial conditions), 6 state variables, and 33 variables. Table VII defines the symbols. Table I outlines peripheral blood lymphocyte doubling time (LDT) and clinical staging [19] . The three parameter types are as follows.
1) Assumed parameters from average human physiology or mathematical analysis-these parameters would be typically clinically unavailable. 2) Measured parameters may be directly determined- Table III proposes experimental methods and Table VII lists typical values. Note that some measurements, e.g., from peripheral blood, may be taken more frequently than from others, such as BM or LN. 3) Calculated parameters that are deduced indirectly-this section proposes a relevant algorithm. Fig. 3 is an example of patient data trajectory within a disease stage. Transition time, or CLL stage duration Δt z = t fin, z − t in, z , is estimated by treating physicians based on changes in PB LDT, increased lymphadenopathy or splenomegaly and low levels of hemoglobin or platelets. Appendixes D and E describe an algorithm we developed in GAMS and MATLAB that finds values of ∀ z ∈ {SN, SA, SB, SC}; this algorithm takes the measurable parameters and deduces reasonable values for the calculated parameters. We seek reasonable parameters rather than guaranteed parameter estimates of the best possible values; our purpose is to capture disease dynamics. We define reasonable parameters as satisfying the Table I disease characteristics and  the Table VII Source column; further model building could augment these restrictions.
C. Global Sensitivity Analysis
We apply random sampling-high-dimensional model representation (RS-HDMR; Appendix F) global sensitivity analysis [35] , [36] to the nominal parameter values. The minimum and maximum values of parameters included in Table IV are used as inputs to the RS-HDMR model analysis (see Table F .1 in Appendix F). The RS-HDMR output variables are the number of proliferative and nonproliferative CLL cells in bone marrow, peripheral blood, and lymp node including S. 
III. CASE STUDIES
The initial characteristics of five hypothetical patients (P1 P5) are posited in Table V . The five hypothetical patients represent a range of clinically relevant physiological conditions (disease heterogeneity) based on common disease presentation (see Table I and Appendixes C-G). The only exception is P3 that represents the model outcome described by Molica et al. [37] , where a patient in Binet Stage A has a lymphocyte doubling time, LDT ≤ 12 months (see Appendix E). The five hypothetical patient trajectories (P1-P5) we model are as follows. [25] , and 6) CLL disease stage duration, Δt z , is based on LDT (see Table I ) and has values [days]: 1000, 1800, 365, 365, and 365 for the five case studies, P1-P5, respectively. We apply the Section II-B algorithm for determining parameters to the five case studies, simulate the trajectories of (1)- (12) and predict future patient signs/sequelae via correlation with the simulated CLL cells number in each disease center. For more detail, see Appendix D. We consider four types of physical signs: 1) high infiltration pattern of BM predicted from (5), 2) only splenomegaly, 3) only lymphadenopathy, and 4) combined splenomegaly and lymphadenopathy (Appendixes C and G). We implemented the model in MATLAB R2013a (8.1.0.604) and GAMS 24. Table VI are based on analyses in Appendixes C and G; Fig. 4 diagrams the MATLAB outputs. The sequel comments on each of the five case studies.
P1 starts from a naïve stage with high LDT and progresses to Binet Stage A (LDT 60 months); the proliferation increase of ≈ 33 months after initial diagnosis correlates with the increased recruitment rates into the bone marrow and lymph node cell cycles. P2 and P3 have similar initial disease characteristics (% CLL cells in bone marrow and %Ki-67) but diverge with respect to initial LDT; these two test cases correspond to work showing that LDT significantly impacts the probability of progression from Binet Stage A to B within a year [37] . The model captures this progression tempo; P2 and P3 progress to Stage B in 60 and 12 months, respectively.
P4 shows a trajectory from Binet Stage B to C where the bone marrow pattern changes from mixed to diffuse and the rate of lymphocyte doubling is roughly constant at 12 months; the fraction of CLL cells migrating decreased or remained stable in the P4 trajectory. Note here that, although the definition of Binet Stage C requires a descriptor of anemia and low platelets (see Table I ), we use instead an indirect metric, assuming that the signs of Binet Stage C will follow from an increase in bone marrow tumor burden. Finally, P5 is an unusual CLL case; the disease initiates slowly in Binet Stage A and bone marrow failure occurs quickly within 2 years.
RS-HDMR analysis of the CLL model in Binet Stages from
A to C, illustrated in Fig. F.2 of Appendix F for 5000 HDMR samples is done in MATLAB with dde23 solver. The parameters (S i ≥ 0.1) of this model that most significantly affect disease trajectory over space and time are: 1) the initial number of CLL cells in peripheral blood, the number of involved (enlarged) lymph nodes and the presence and degree of splenomegaly, 2) the migratory fractions of non-proliferating as well as proliferating CLL cells from bone marrow into peripheral blood and of proliferating CLL cells from peripheral blood to lymph nodes, and 3) the parameter inducing non-proliferative cells to proliferate. Several critical parameters identified by our model (enlarged lymph nodes, splenomegaly, LDT) are already used in staging systems, but none of: 1) total CLL cell number, 2) migration rate, and 3) propensity to induce proliferation (unless directly incurred by a known mutation, e.g., p53, or mutated pathway) is currently used. We, therefore, propose these factors for inclusion in multiparameter models of disease progression, as targets for prevention of progression or therapy. In particular, the use of migration rate, e.g., using chemokine or integrin surface markers or other relevant serum biomarkers, and the induction of a cell proliferation profile, e.g., via mutated cell cycle checkpoints or intracellular pathways such as PI3K, could be important focal points for inclusion in future research. These parameters could be made readily available for input into models on a patient-specific basis over the disease course from peripheral blood tests done at the bedside (for migration assessments) and from sampling of the primary disease center, e.g., lymph node or bone marrow for proliferation parameters via fine needle aspirate or core biopsy-both routine procedures.
Expression of Ki-67, a proliferation marker found in cycle phases G1, S, G2, and M but not G0 [40] , is found in tissues affected by CLL in varying percentage: peripheral blood 0.36 ± 0.34%, bone marrow 2.48 ± 0.77%, and lymph nodes and spleen 4.95 ± 0.55% [26] . In addition to having higher proliferative features than those of bone marrow or peripheral blood, lymph nodes, and spleen disease centers in CLL also have lower death rates [33] , [34] , a feature that has been partially attributed to the microenvironment [41] . One of the earliest mathematical frameworks of CLL models the interaction between CLL cells and T-cells, a component of the microenvironment, via a Volterra predator-prey equation [42] . A kinetic model [30] has also been used to develop the first model of CLL incorporating interactions between CLL cells, natural killer (NK) cells, cytotoxic (CD8+) T-cells, and helper (CD4+) T-cells [43] . This model implicitly assumes that the entire body is one compartment, and thereby, does not account for the proliferation center microenvironment, disease center carrying capacity, or the cellular migration between disease centers [43] . CLL lymphocytosis kinetics have been studied using a two-compartment model [30] that characterizes CLL cell redistribution dynamics from proliferation centers into the peripheral blood induced by the novel BTK inhibitor, Ibrutinib albeit there is little known about steady-state dynamics or of that which occurs during the natural course of disease [44] .
Variations may assume different cell cycle models for each disease compartment. For example, immunophenotyping to distinguish between B-and T-cells in the peripheral blood lymphocyte compartment [41] , [45] that may facilitate the incorporation of immune interactions and current immunochemotherapeutic targets [46] . Our model, therefore, complements the one-compartment model of Nanda et al. [43] . If we could assume data on T-cell populations, i.e., CD4+, CD8+, the Nanda et al. [43] model could replace each G0 model in Fig. 1 . This manuscript does not use the optional T-cell module and reflects data availability from typical clinical protocols with first-order approximation that 90% of lymphocytes in affected tissues are CLL cells [41] . Our model meaningfully adapts to each of the disparate case studies and the parameters and variables adhere to physiologically relevant values. The proposed framework has been developed using a variety of hypothetical test cases. However, used in tandem with real patient data and other clinical diagnostic tools [47] , [48] , the developed algorithm may enable patient-specific, leukemia-specific disease dynamic modeling for actual patients with CLL. It also provides insight into the trajectory of disease progression and presents CLL cell migration and propensity toward proliferation as avenues of future research.
V. CONCLUSION
This paper develops the first physiologically relevant mathematical model of CLL connecting the most affected tissues. The mathematical novelty stems from the integration of both temporal and spatial CLL aspects. The delay differential equations incorporate the temporal aspect of cell division. The model is practical in that 1) measurable input parameters have been taken from common clinical protocols, 2) from data that is readily accessible in current standard clinical practice, 3) it captures physiologically relevant transitions from Binet Stage A to C, and 4) it predicts outcomes that may be clinically useful for expectant patient care if validated using primary patient data. Using the model, we found that CLL cell migration between disease centers and the induction of CLL cells into proliferative phase are critical parameters determining disease evolution and should be evaluated in future research.
